Five Fisons products will be developed using Hollywood, Fla. based Himedics' delivery system for pediatric patients and others with difficulty swallowing. Licensing, supply and development agreement announced June 28. The products are: amoxicillin, erythromycin, acetaminophen, dicloxacillin and prednisone. Himedics' system processes drugs into taste-free microgranules that can be metered onto soft food for dosing. Fisons will hold exclusive rights to market and distribute the products in the U.S. in exchange for licensing fees totaling $ 3.5 mil. Himedics will develop and manufacture the products.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.